

**WE CLAIM :**

An antituberculous therapeutic drug comprising:

(I) at least one selected from the group consisting of 2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy) piperidin-1-yl]phenoxyethyl}-2,3-dihydroimidazo[2,1-b] oxazole, optically active forms thereof and pharmaceutically acceptable salts thereof, and

(II) a primary antituberculous drug,

wherein a weight ratio of the at least one selected from the group consisting of 2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy) piperidin-1-yl]phenoxyethyl}-2,3-dihydroimidazo[2,1-b] oxazole, optically active forms thereof and pharmaceutically acceptable salts thereof and at least one of the primary antituberculous drugs is about 1:0.01-1:100.

2. The antituberculous therapeutic drug according to claim 1, wherein the primary antituberculous drug is at least one selected from the group consisting of rifamycin and related anti-bacterial drugs, isoniazid, ethambutol, streptomycin, pyrazinamide and salts thereof.

3. The antituberculous therapeutic drug according to claim 1, wherein the at least one selected from the primary antituberculous drugs comprises in combination

- (i) at least one of rifamycin and related anti-bacterial drugs and
- (ii) at least one selected from the group consisting of isoniazid, ethambutol streptomycin, pyrazinamide and salts thereof.

4. The antituberculous therapeutic drug according to claim 1, wherein the at least one selected from the primary antituberculous drugs comprises in combination

- (i) at least one of rifamycin and related anti-bacterial drug(s),
- (ii) pyrazinamide, and
- (iii) at least one selected from the group consisting of isoniazid ethambutol and streptomycin.

5. The anticuberculous therapeutic drug according to any one of claims 2 to 4, wherein the at elast one of rifamycin and related anti-bacterial drugs is at least one selected from the group consisting of rifampicin, rifabutin and rifapentine.

Dated this 27th day of March, 2008



S BANERJEE  
L S DAVAR & CO  
APPLICANTS' AGENT